Key Takeaways Lilly's phase III BRUIN CLL-313 trial met its main goal with Jaypirca in untreated CLL/SLL patients.Jaypirca delivered a significant progression-free survival benefit versus chemoimmunotherapy.Overall survival trended favorably for Jaypirca, with final analysis expected in 2026.Eli Lilly (LLY) announced that the phase III BRUIN CLL-313 study, evaluating its BTK inhibitor Jaypirca (pirtobrutinib) versus chemoimmunotherapy (bendamustine plus rituximab) in treatment-naïve patients with chronic ly ...

Key Takeaways Lilly's oncology sales hit $4.4B in H1 2025, up 10% and constituting about 15% of total revenues.Portfolio spans older drugs like Alimta and Erbitux to newer assets, Jaypirca and Retevmo.Imlunestrant, under review in the U.S. and EU, could soon expand Lilly's oncology growth drivers.Eli Lilly’s (LLY) extraordinary revenue expansion remains anchored in its cardiometabolic franchise, where blockbuster GLP-1 drugs Mounjaro and Zepbound powered $20.6 billion in sales during the first half of 2025, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Investment Rating - The report maintains a "Buy" rating for the GLP-1 receptor agonists (GLP-1RAs) market, highlighting its leadership in the diabetes and weight loss sectors with potential for further indication development [2]. Core Insights - The development trends for GLP-1RAs include multi-targeting, long-acting formulations, and oral administration, which enhance patient compliance and convenience compared to traditional injectable forms [4][107]. - GLP-1RAs demonstrate significant efficacy in metabolic diseases, with a broad scope for expanding indications, including diabetes, obesity, and cardiovascular protection [7][21][27]. - The global diabetes market is projected to reach nearly $80 billion by 2024, with China's market exceeding 70 billion yuan, establishing a strong foundation for GLP-1RAs [7][42]. - The obesity market is expanding rapidly, with overweight and obese populations expected to reach 2.5 billion by 2025, representing 46% of the global adult population, thus creating substantial market opportunities for weight loss medications [7][82]. Summary by Sections 1. Efficacy of GLP-1RAs in Diabetes and Obesity - GLP-1RAs show excellent efficacy across multiple indications, including diabetes and obesity, with mechanisms that enhance insulin secretion and suppress appetite [10][21]. - The global market for GLP-1RAs is rapidly growing, with sales expected to reach nearly $50 billion by 2024, driven by products like semaglutide and tirzepatide [39][65]. 2. Diabetes: Revolutionizing Treatment with GLP-1RAs - The diabetes drug market is vast, with a significant increase in the number of diabetes patients, which supports the growth of GLP-1RAs as a new treatment option [42][47]. - GLP-1RAs are becoming the preferred choice for diabetes management due to their dual benefits of glycemic control and weight loss [48][55]. 3. Weight Loss: GLP-1RAs' Promising Efficacy and Market Potential - The weight loss drug market is expanding, with GLP-1RAs showing superior efficacy compared to traditional weight loss medications, making them a focal point for pharmaceutical development [87][93]. - Three GLP-1RAs have received FDA approval for weight loss, with semaglutide leading in sales and effectiveness [93][95]. 4. Development Trends: Multi-targeting, Long-acting, and Oral Formulations - The future of GLP-1RAs is leaning towards oral formulations, which are expected to improve patient adherence and convenience [107][108]. - The introduction of dual-target and multi-target GLP-1RAs is anticipated to enhance treatment outcomes and market competitiveness [68][62].

Accessibility StatementSkip Navigation Acclaimed actress, author, and advocate Julianne Moore joins cause in the United States to encourage early, ongoing brain health conversations between people and their doctors Nearly four in five Americans say they would want to know if they have Alzheimer's disease before symptoms interfere with daily activities, highlighting the growing desire for open conversations and early detection With the number of people aged 65 and older with Alzheimer's dementia projected to ...

Group 1 - Eli Lilly is launching an artificial intelligence and machine learning platform for biotech companies [1] - The platform will provide access to drug discovery models based on years of Eli Lilly's research data [1]

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced an agreement with Eli Lilly and Company (Lilly) that enables the company to use Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug. ...

Core Viewpoint - Eli Lilly is experiencing significant stock appreciation and is expected to report strong earnings and revenue growth in its upcoming earnings disclosure Group 1: Stock Performance - Eli Lilly's stock increased by 1.51% to $738.17, outperforming the S&P 500's daily gain of 0.21% [1] - Over the past month, Eli Lilly's shares have appreciated by 16.23%, compared to the Medical sector's gain of 5.47% and the S&P 500's gain of 3.07% [1] Group 2: Earnings and Revenue Estimates - Analysts expect Eli Lilly to post earnings of $6.42 per share, reflecting a year-over-year growth of 444.07% [2] - The revenue forecast for the upcoming quarter is $16.05 billion, indicating a 40.32% growth compared to the same quarter last year [2] - For the full year, earnings are projected at $23.03 per share and revenue at $61.81 billion, representing changes of +77.29% and +37.22% from the prior year, respectively [3] Group 3: Analyst Estimates and Rankings - Changes in analyst estimates for Eli Lilly are crucial as they reflect the evolving business trends and analysts' confidence in the company's profitability [4] - The Zacks Rank system, which incorporates estimate changes, currently ranks Eli Lilly at 3 (Hold) [6] Group 4: Valuation Metrics - Eli Lilly has a Forward P/E ratio of 31.58, which is a premium compared to the industry average of 14.41 [7] - The company holds a PEG ratio of 1.02, compared to the industry average PEG ratio of 1.37 [7] Group 5: Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 160, placing it in the bottom 36% of all industries [8]

Core Strategy - The company has undertaken a significant reboot of its R&D strategy in oncology to enhance productivity and sustainability within the organization [2] Historical Context - Historically, the company has developed and marketed several important medicines in oncology, including chemotherapies [2]

Core Insights - Ozempic and Zepbound have transitioned from diabetes treatments to cultural phenomena, contributing to a combined market cap of over $900 billion for Novo Nordisk A/S and Eli Lilly And Co [1] - The GLP-1 market is projected to exceed $150 billion by 2030, indicating significant growth potential in the pharmaceutical sector [3][4] Group 1: Cultural Impact - Celebrity endorsements have heightened interest in GLP-1s, making them both aspirational and controversial, with figures like Serena Williams and Amy Schumer sharing their experiences [2] - The narrative around GLP-1s has shifted from a wellness trend to a mainstream healthcare option, driven by high-profile users and effective telehealth strategies [5] Group 2: Financial Implications - The surge in prescriptions for GLP-1 therapies is not merely hype; it reflects a broader trend towards their use in heart health, diabetes prevention, and cognitive benefits [4] - The financial outlook for GLP-1 therapies positions them as some of the most lucrative products in modern pharmaceuticals, with PWC forecasting a market value of $150 billion by 2030 [3]